Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00183820 · OUTCOME

Tumor Response

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years

What was measured

Defined as the best response recorded from the start of treatment until disease progression/recurrence, evaluated according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in the sum of the diameters of the target lesions compared to the baseline; Stable Disease = Neither enough shrinkage for PR nor enough growth for PD; Progressive Disease = at least a 20% increase in the sum of the diameters of the target lesions from the smallest measurement recorded, with an absolute increase of at least 5 mm, or the appearance of one or more new lesions.

Analysis population: 1 patient was inevaluable.

Groups in this outcome

Paclitaxel, Gemcitabine, and Oxaliplatin

paclitaxel, gemcitabine, and oxaliplatin: 1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Paclitaxel, Gemcitabine, and Oxaliplatin29

Reported measurements

Source class 1

Complete Response (CR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Gemcitabine, and Oxaliplatin2Not reportedNot reportedNot reportedNot reported

Partial Response (PR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Gemcitabine, and Oxaliplatin7Not reportedNot reportedNot reportedNot reported

Stable Disease (SD)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Gemcitabine, and Oxaliplatin15Not reportedNot reportedNot reportedNot reported

Progressive Disease (PD)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Gemcitabine, and Oxaliplatin5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      title
      Complete Response (CR)
    2. measurements
      1. group Id
        OG000
        value
        7
      title
      Partial Response (PR)
    3. measurements
      1. group Id
        OG000
        value
        15
      title
      Stable Disease (SD)
    4. measurements
      1. group Id
        OG000
        value
        5
      title
      Progressive Disease (PD)
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
description
Defined as the best response recorded from the start of treatment until disease progression/recurrence, evaluated according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in the sum of the diameters of the target lesions compared to the baseline; Stable Disease = Neither enough shrinkage for PR nor enough growth for PD; Progressive Disease = at least a 20% increase in the sum of the diameters of the target lesions from the smallest measurement recorded, with an absolute increase of at least 5 mm, or the appearance of one or more new lesions.
groups
  1. description
    paclitaxel, gemcitabine, and oxaliplatin: 1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days
    id
    OG000
    title
    Paclitaxel, Gemcitabine, and Oxaliplatin
param Type
COUNT_OF_PARTICIPANTS
population Description
1 patient was inevaluable.
reporting Status
POSTED
time Frame
From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years
title
Tumor Response
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice